Qualigen Therapeutics, INC

AIxCrypto Holdings reported its second quarter 2026 results, highlighting the launch of its RoboShare platform and a significant sequential decrease in operating expenses, but also substantial net losses and a depleted cash position.

AIxCrypto Holdings, Inc. has entered into a material definitive agreement for consulting services with Aibot US Operation Inc., effective July 16, 2026.

AIxCrypto Holdings, Inc. has entered into a common shares purchase agreement for a private placement offering of up to $50 million.

AIxCrypto Holdings announces a major executive leadership transition and the strategic wind-down of its legacy biotechnology business.

AIxCrypto Holdings, Inc. has entered into a note purchase agreement to sell its interest in a package of notes and related security agreements to CABG Acquisition Corp.

Faraday Future Intelligent Electric Inc. has entered into an amended securities purchase agreement with Gold King Arthur Holding Limited to raise $12 million in capital.

AIxCrypto Holdings reported substantial net losses and significant cash burn, raising serious concerns about its ability to continue as a going concern, despite a strategic pivot towards AI and digital assets.

AIxCrypto Holdings reports a significant strategic pivot towards RWA tokenization and Embodied AI, with Q1 2026 results reflecting increased operational costs and a substantial net loss.

Qualigen Therapeutics, Inc. reported a significant capital raise of $41 million, primarily for new cryptocurrency treasury operations, despite ongoing operational losses and substantial doubt about its ability to continue as a going concern.

Qualigen Therapeutics reports significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Qualigen Therapeutics, Inc. reported a significant increase in net loss and a drastic reduction in cash reserves for Q1 2025, raising substantial doubt about its ability to continue as a going concern, despite ongoing efforts to raise capital.

Qualigen Therapeutics reports a net loss of $1.8 million for Q3 2024, with ongoing concerns about its ability to continue as a going concern.

AIxCrypto Holdings reported a $17.0M 2025 net loss, rebranded from Qualigen, raised $41M, built a $10.3M crypto treasury, and narrowed its strategy to real‑world asset tokenization and embodied AI while warning of going concern risks and heavy dilution.

Qualigen Therapeutics, an early-clinical-stage oncology company, reported a significant net loss and accumulated deficit for 2024, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice and a slowdown in its core therapeutic programs.

Qualigen Therapeutics reports its full year 2023 results, highlighting a strategic shift towards therapeutics and away from diagnostics, while facing financial challenges.

AIxCrypto Holdings, Inc. announces its 2024 Annual Meeting for December 2025, detailing director elections, executive compensation, and auditor changes amidst continued net losses.

Qualigen Therapeutics, Inc. is convening a Special Meeting on November 12, 2025, to seek stockholder approval for a $41 million private placement, a new equity incentive plan, and related share issuances.

Qualigen Therapeutics supplements its proxy statement, providing updated information on director nominees for the upcoming annual meeting on October 25, 2024.

Qualigen Therapeutics is holding its 2024 Annual Meeting of Stockholders on October 25, 2024, to vote on key proposals including a reverse stock split, director elections, and ratification of the company's independent accounting firm.

AIxCrypto Holdings, Inc. has filed an S-1 registration statement to allow for the resale of up to 55 million shares of common stock by a selling stockholder, potentially raising up to $50 million through a volume-weighted average price (VWAP) purchase agreement.

AIxCrypto Holdings, Inc. files S-1 for the resale of 18.1 million common shares by selling stockholders, signaling a strategic shift to cryptocurrency treasury operations and addressing Nasdaq compliance.

Qualigen Therapeutics files S-1 to register up to 3.2 million common shares for resale by existing Series A-3 Preferred stockholders, with no proceeds going to the company.

Qualigen Therapeutics is registering for resale up to 3,436,281 shares of common stock issuable upon conversion of Series A-2 Preferred Stock held by selling stockholders.

Qualigen Therapeutics aims to raise up to $1.8 million through a public offering of common stock and pre-funded warrants to fund operations, marketing, and potential acquisitions.

Qualigen Therapeutics aims to raise up to $4 million through a public offering of common stock and pre-funded warrants to advance its clinical programs and for general corporate purposes.

Faraday Future Intelligent Electric Inc. has increased its beneficial ownership in Qualigen Therapeutics, Inc. to 19.99% following the conversion of Series B Preferred Stock.

Faraday Future Intelligent Electric Inc. has acquired an 8.0% stake in Qualigen Therapeutics, Inc., initiating a strategic pivot towards cryptocurrency and significant governance changes.

Alpha Capital Anstalt has filed an Amendment No. 4 to Schedule 13G, reporting beneficial ownership of 0.51% of ALXCRYPTO HOLDINGS, INC. common stock.

Alpha Capital Anstalt has reported a 9.056% beneficial ownership stake in Qualigen Therapeutics, Inc., holding 153,545 shares of common stock.

Alpha Capital Anstalt has updated its beneficial ownership in Qualigen Therapeutics, Inc., reporting a 2.223% stake.